Madrigal Pharmaceuticals has a first mover advantage in the huge MASH market due to the approval of Rezdiffra. Read whether I ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

Roche is rolling out a new diagnostic test to help assess hidden liver fibrosis in patients showing signs of metabolic ...

We recently published a list of Billionaire John Paulson’s 10 Stocks with Huge Upside Potential. In this article, we are ...

Discover Madrigal Pharmaceuticals' impressive Q1 2025 earnings, with Rezdiffra's 33% sales growth, expanded market reach, and upcoming European launch plans.

Rezdiffra sales reached $137 million for the quarter, beating consensus analyst estimates by more than $20 million and ...

Madrigal Pharmaceuticals Inc (MDGL) reports a 33% increase in net sales and significant patient growth, while navigating ...

Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as ...

First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO ...

During the quarter, the company generated total revenues of $137.3 million, entirely from product sales of its metabolic dysfunction-associated steatohepatitis (MASH) drug Rezdiffra (resmetirom ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.